Literature DB >> 10354141

Increased sensitivity of CLL-derived lymphocytes to apoptotic death activation by the proteasome-specific inhibitor lactacystin.

P Masdehors1, S Omura, H Merle-Béral, F Mentz, J M Cosset, J Dumont, H Magdelénat, J Delic.   

Abstract

Ubiquitin-proteasome-dependent protein processing appears to be an essential component in the control of radiation-induced apoptosis in human lymphocytes. This control is altered in chronic lymphocytic leukaemia (CLL), compared to that of normal human lymphocytes which mainly showed high apoptotic values after irradiation, but in some cases no sensitivity was observed. Interestingly, lactacystin activated the apoptotic pathway in both radio-resistant and sensitive CLL cells, at doses which had no effect in normal cells where significantly higher concentrations were required. Therefore the resistance of some CLL cells to apoptosis initiation by radiation does not correlate to observed increased sensitivity to lactacystin. The nuclear level of the transcription factor NF-kappaB or the cytoplasmic level of IkappaBalpha remained unaltered upon irradiation or lactacystin CLL cells treatment, suggesting that the activity of the other factors involved in apoptotic death control were altered through proteasomal inhibition. These results strongly suggest an essential role of the ubiquitin system in apoptotic cell death control in CLL lymphocytes. The inhibition of proteasome-ubiquitin-dependent processing could be a discriminatory apoptotic stimulus between normal versus malignant lymphocytes and therefore might potentially be of use in this specific human pathology.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10354141     DOI: 10.1046/j.1365-2141.1999.01388.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  12 in total

Review 1.  Plant proteolytic enzymes: possible roles during programmed cell death.

Authors:  E P Beers; B J Woffenden; C Zhao
Journal:  Plant Mol Biol       Date:  2000-10       Impact factor: 4.076

2.  The ubiquitin-proteasomal system is critical for multiple myeloma: implications in drug discovery.

Authors:  Biyin Cao; Xinliang Mao
Journal:  Am J Blood Res       Date:  2011-05-25

3.  Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells.

Authors:  Esther A Obeng; Louise M Carlson; Delia M Gutman; William J Harrington; Kelvin P Lee; Lawrence H Boise
Journal:  Blood       Date:  2006-02-28       Impact factor: 22.113

Review 4.  The proteasome: a novel target for anticancer therapy.

Authors:  C Montagut; A Rovira; J Albanell
Journal:  Clin Transl Oncol       Date:  2006-05       Impact factor: 3.405

Review 5.  The ubiquitin-proteasome system as a prospective molecular target for cancer treatment and prevention.

Authors:  Di Chen; Q Ping Dou
Journal:  Curr Protein Pept Sci       Date:  2010-09       Impact factor: 3.272

6.  Enhanced delivery of cisplatin to intraperitoneal ovarian carcinomas mediated by the effects of bortezomib on the human copper transporter 1.

Authors:  Danielle D Jandial; Salman Farshchi-Heydari; Christopher A Larson; Gregory I Elliott; Wolfgang J Wrasidlo; Stephen B Howell
Journal:  Clin Cancer Res       Date:  2009-01-15       Impact factor: 12.531

Review 7.  Therapeutic strategies to enhance the anticancer efficacy of histone deacetylase inhibitors.

Authors:  Claudia P Miller; Melissa M Singh; Nilsa Rivera-Del Valle; Christa A Manton; Joya Chandra
Journal:  J Biomed Biotechnol       Date:  2011-06-28

8.  The proteasome inhibitor MG-132 sensitizes PC-3 prostate cancer cells to ionizing radiation by a DNA-PK-independent mechanism.

Authors:  Frank Pajonk; Arndt van Ophoven; Christian Weissenberger; William H McBride
Journal:  BMC Cancer       Date:  2005-07-07       Impact factor: 4.430

9.  Targeting Notch1 and proteasome as an effective strategy to suppress T-cell lymphoproliferative neoplasms.

Authors:  Lujun Yang; Shuangfeng Zhang; Suraj Konnath George; Rong Teng; Xuefen You; Mengqi Xu; Hong Liu; Xiaoping Sun; Hesham M Amin; Wenyu Shi
Journal:  Oncotarget       Date:  2015-06-20

Review 10.  Targeting the UPS as therapy in multiple myeloma.

Authors:  Dharminder Chauhan; Giada Bianchi; Kenneth C Anderson
Journal:  BMC Biochem       Date:  2008-10-21       Impact factor: 4.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.